

EXPRESS MAIL NO. EV335610938US

Sheet 1 of 2

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C26		APPLICATION NO. 09/895,814		
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Jiangchun Xu et al.				
				FILING DATE June 29, 2001		GROUP ART UNIT 1642		
U.S. PATENT DOCUMENTS								
DOCUMENT NUMBER		DATE		NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA 6,329,505		12/11/01		Xu et al.		530	350	
AB								
FOREIGN PATENT DOCUMENTS								
DOCUMENT NUMBER		DATE		COUNTRY		TRANSLATION YES NO		
AC WO 99/67384		12/29/99		WIPO				
AD WO 00/53772		09/14/00		WIPO				
AE WO 00/53776		09/14/00		WIPO				
AF WO 00/71711		11/30/00		WIPO				
AG WO 00/73801		12/07/00		WIPO				
AH WO 01/16289		03/08/01		WIPO				
AI WO 01/23587		04/05/01		WIPO				
AJ WO 01/25446		04/12/01		WIPO				
AK WO 01/57272		08/09/01		WIPO				
AL WO 02/077243		10/03/02		WIPO				
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
AP		Nelson, P.S. et al., "Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression," <i>Proc. Natl. Acad. Sci. USA</i> 96: 3114-3119, March 1999.						
AQ		Stephenson, S-A., "Localization of a New Prostate-specific Antigen-related Serine Protease Gene, <i>KLK4</i> , Is Evidence for a Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3-13.4," <i>The Journal of Biological Chemistry</i> 274(33): 23210-23214, August 13, 1999.						
AR		Yousef, G. M. et al., "Protease/ <i>KLK-L1</i> Is a New Member of the Human Kallikrein Gene Family, Is Expressed in Prostate and Breast Tissues, and Is Hormonally Regulated," <i>Cancer Research</i> 59: 4252-4256, September 1, 1999.						
EXAMINER				DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).				2/1/05				

9/12/06

EXPRESS MAIL NO. EV335610938US

Sheet 2 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C26

APPLICATION NO.

097895,814

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
			YES	NO
BB				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SC	BC	GenBank Database, Accession No. AAD26424, October 27, 1999. Available at http://www.ncbi.nlm.nih.gov .
	BD	GenBank Database, Accession No. AAD38019, October 15, 1999. Available at http://www.ncbi.nlm.nih.gov .
	BE	GenBank Database, Accession No. AAF70620, July 10, 2000. Available at http://www.ncbi.nlm.nih.gov .
	BF	GenBank Database, Accession No. AAF81227, July 2, 2000. Available at http://www.ncbi.nlm.nih.gov .
	BG	GenBank Database, Accession No. AAG43246, January 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BH	GenBank Database, Accession No. AAK71700, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BI	GenBank Database, Accession No. AAK71701, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BJ	GenBank Database, Accession No. AAK71702, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BK	GenBank Database, Accession No. AAK71703, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BL	GenBank Database, Accession No. AAK71704, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BM	GenBank Database, Accession No. AAK71705, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
	BN	GenBank Database, Accession No. AAK71706, August 2, 2001. Available at http://www.ncbi.nlm.nih.gov .

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered; whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

Sheet 3 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
			YES	NO
CB				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CC	GenBank Database, Accession No. AF113140, March 25, 1999. Available at http://www.ncbi.nlm.nih.gov .
CD	GenBank Database, Accession No. AF126401, January 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
CE	GenBank Database, Accession No. AF135023, October 27, 1999. Available at http://www.ncbi.nlm.nih.gov .
CF	GenBank Database, Accession No. AF228497, July 10, 2000. Available at http://www.ncbi.nlm.nih.gov .
CG	GenBank Database, Accession No. AF243527, November 21, 2000. Available at http://www.ncbi.nlm.nih.gov .
CH	GenBank Database, Accession No. AF259969, July 2, 2000. Available at http://www.ncbi.nlm.nih.gov .
CI	GenBank Database, Accession No. NM_004917, October 27, 1999. Available at http://www.ncbi.nlm.nih.gov .
CJ	GenBank Database, Accession No. NP_004908, October 27, 1999. Available at http://www.ncbi.nlm.nih.gov .
CK	GenBank Database, Accession No. XP_008997, May 2, 2001. Available at http://www.ncbi.nlm.nih.gov .
CL	GenBank Database, Accession No. XP_031752, October 16, 2001. Available at http://www.ncbi.nlm.nih.gov .
CM	
CN	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

JUN 06 2005

Sheet 4 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GA DA	5,786,148	07/28/98	Bandman et al.	435	6	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
DB	DE 19649207	11/27/96	Germany	
DC	EP 317,141 A2	05/24/89	EPO	
DD	EP 652,014 A1	5/10/95	EPO	
DE	EP 679,716 A1	11/02/95	EPO	
DF	EP 936,270 A2	08/18/99	EPO	X
DG	WO 93/14755	08/05/93	PCT	
DH	WO 93/25224	12/23/93	PCT	
DI	WO 94/09820	05/11/94	PCT	
DJ	WO 95/04548	02/16/95	PCT	
DK	WO 95/14772	06/01/95	PCT (Cover page with English abstract only)	X
DL	WO 95/30758	11/16/95	PCT	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DM	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
DN	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
DO	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
DP	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
DQ	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Put line across this form with next communication to applicant(s).

9/12/06

EXPRESS MAIL NO. EV335610938US

Sheet 5 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C26APPLICATION NO.
09/895,814THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	EB	WO 96/21671	07/18/96	PCT		
	EC	WO 97/33909	09/18/97	PCT		
	ED	WO 98/2302	03/26/98	PCT		
	EE	WO 98/17687	04/30/98	PCT		
	EF	WO 98/20117	05/14/98	PCT		
GM	EG	WO 98/31799	07/23/98	PCT		
	EH	WO 98/37093	08/27/98	PCT		
	EI	WO 98/37418	08/27/98	PCT		
	EJ	WO 98/38310	09/03/98	PCT		
	EK	WO 98/39446	09/11/98	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EL	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
EM	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.
EN	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
EO	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
EP	Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

Sheet 6 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

* EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
SM	FB	WO 98/45435	10/15/98	PCT		
	FC	WO 98/50567	11/12/98	PCT		
	FD	WO 99/06548	02/11/99	PCT		
	FE	WO 99/06552	02/11/99	PCT		
	FF	WO 99/06550	02/11/99	PCT		
	FG	WO 99/25825	05/27/99	PCT		
	FH	WO 99/31236	06/24/99	PCT		
	FI					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FJ	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
FK	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
FL	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions." Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent 198 29649201 C1.
FM	El-Shirbiny, "Prostatic Specific Antigen," <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.
FN	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.
FO	GenBank Accession Number AF047020, February 1, 1999.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not it is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

Sheet 7 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP/ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
GB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GC	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
GD	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.
GE	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.
GF	Hillier et al., Genbank Accession No. R20590, April 18, 1995.
GG	Hudson, T., Genbank Accession No. G22461, May 31, 1996.
GH	Kroger, B. "New serine protease from human prostate, useful for identifying specific inhibitors, antibodies and probes." Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
GI	Lalvan et al., "Rapid effector function in CD8 ⁺ memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 13, 1997.
GJ	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
GK	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
GL	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV335610938US

JUN 06 2005

Sheet 8 of 9

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

210121.427C26

09/895,814

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
HB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HC	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.
HD	Robson et al., "Identification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.
HE	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.
HF	Schmidt-Wolf et al., "Activated T cells and cytokine-induced CD3 ⁺ CD56 ⁺ killer cells," <i>Annals of Hematology</i> 74:51-56, 1997.
HO	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5093):815-818, October 30, 1992.
HH	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
HI	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
HJ	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.
HK	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
HL	Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.427C26

APPLICATION NO.

09/895,814

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
IA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
IB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IC	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.
ID	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
IE	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.
IF	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.
IG	
IH	
II	
IJ	
IK	
IL	

EXAMINER:

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).